Is Strattera (Atomoxetine) allowed for Department of Transportation (DOT) purposes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 8, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

From the Guidelines

Strattera (atomoxetine) is generally allowed for commercial drivers under Department of Transportation (DOT) regulations. Unlike stimulant medications used for ADHD such as Adderall or Ritalin, Strattera is not a controlled substance and does not cause the same concerns about alertness impairment or potential for abuse 1. Commercial drivers with ADHD who need medication can typically use Strattera while maintaining their commercial driver's license (CDL). However, the driver should work closely with their healthcare provider to ensure proper dosing and monitoring for side effects. During the initial adjustment period to Strattera, some individuals may experience drowsiness or dizziness, so it's advisable to understand how the medication affects you before operating commercial vehicles. The medical examiner performing the DOT physical should be informed about all medications being taken, including Strattera, to make an appropriate fitness determination. Strattera works differently than stimulants by selectively inhibiting norepinephrine reuptake, which helps improve attention and reduce impulsivity without the central nervous system stimulant effects that concern DOT regulators.

Some key points to consider when using Strattera for commercial drivers with ADHD include:

  • Monitoring for signs of misuse or diversion of ADHD medication, as noted in the 2011 clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents 1
  • Providing medication coverage for symptom control while driving, with longer-acting or late-afternoon, short-acting medications potentially being helpful in this regard 1
  • Ensuring proper dosing and monitoring for side effects, as well as informing the medical examiner performing the DOT physical about all medications being taken, including Strattera

It's worth noting that the 2024 study on attention-deficit/hyperactivity disorder in pregnancy and the postpartum period highlights the importance of treatment in improving driving capability, particularly in individuals with severe or untreated ADHD 2. However, this study does not directly address the use of Strattera in commercial drivers, and the 2011 guideline remains the most relevant evidence for this specific question.

From the Research

Strattera and DOT

  • Strattera, also known as atomoxetine, is a selective norepinephrine reuptake inhibitor used to treat attention-deficit hyperactivity disorder (ADHD) in children, adolescents, and adults 3, 4, 5.
  • The US Food and Drug Administration approved atomoxetine for the treatment of ADHD in 2002, and it is considered a non-stimulant option for patients who are at risk for substance abuse or do not wish to take a controlled substance 4, 5.
  • Atomoxetine is not classified as a stimulant and is not a controlled substance in the US, which makes it a valuable option for patients who require treatment for ADHD but may be at risk for substance abuse 3, 4.
  • The medication has been shown to be effective in improving ADHD symptoms, quality of life, and emotional lability, with a median time to response of 3.7 weeks 5.
  • Atomoxetine can be administered once or twice daily, and its dosage regimen can be adjusted based on the patient's response to treatment and their CYP2D6 genotype 6.

Safety and Efficacy

  • Atomoxetine has been found to be generally well tolerated, with common adverse events including headache, abdominal pain, decreased appetite, vomiting, somnolence, and nausea 3, 4.
  • The medication has a negligible risk of abuse or misuse, and its subjective-effects profile is different from that of methylphenidate 4.
  • Atomoxetine has been shown to be safe and effective in combination with stimulants, and it has been studied systematically in subjects with ADHD and comorbid oppositional defiant disorder, anxiety, depression, and substance use disorders 5.
  • However, atomoxetine should not be given to patients with known cardiovascular problems, and all adult patients who receive atomoxetine should be monitored for changes in blood pressure throughout treatment 7.

DOT Regulations

  • There is no direct evidence in the provided studies regarding the use of Strattera in relation to Department of Transportation (DOT) regulations.
  • However, given that atomoxetine is not a controlled substance and has a negligible risk of abuse or misuse, it is likely that it would be allowed for use by individuals subject to DOT regulations, but this would depend on the specific regulations and guidelines in place.

References

2
Guideline

attention-deficit/hyperactivity disorder in pregnancy and the postpartum period.

American Journal of Obstetrics and Gynecology, 2024

5
Research

A critical appraisal of atomoxetine in the management of ADHD.

Therapeutics and clinical risk management, 2016

Related Questions

When should I take the two 40 mg doses of atomoxetine each day?
Is it safe to stop taking Strattera (Atomoxetine) on weekends for Attention Deficit Hyperactivity Disorder (ADHD)?
Is it appropriate to add Strattera (atomoxetine) for attention‑deficit/hyperactivity disorder to my current treatment with sertraline and aripiprazole, and how should it be dosed and monitored?
A patient on Strattera (atomoxetine) 60 mg reports persistent difficulty concentrating and focusing; what advice should be given?
Can Straterra (atomoxetine) cause increased anxiety in patients, particularly those with a history of anxiety disorders, such as a child or adult with Attention Deficit Hyperactivity Disorder (ADHD)?
What is the sensitivity and specificity of the Campylobacter antigen Enzyme Immunoassay (EIA) for stool?
How to manage muscle cramping exacerbated by initiation of 50 mg sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI)?
What is the next step for a 54-year-old male patient with persistent chest pain, who had a negative cardiac catheterization for coronary artery disease (CAD) and only reached 72% of the target heart rate during a stress test, which induced shortness of breath, chest tightness, and a hypertensive blood pressure response without electrocardiogram (EKG) changes?
What is the cause and workup of a thick 30mm endometrial stripe in a 49-year-old woman with an Intrauterine Device (IUD) and abnormal uterine bleeding?
What is the recurrence rate for lipoma after surgical excision?
Is Elavil (Amitriptyline) used for gastroesophageal reflux disease (GERD)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.